- Home
- CRBP vs NKTR Comparison
CRBP vs NKTR Comparison
Compare CRBP & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- NKTR
- Stock Information
- Founded
- CRBP 2009
- NKTR 1990
- Country
- CRBP United States
- NKTR United States
- Employees
- CRBP N/A
- NKTR N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- CRBP Health Care
- NKTR Health Care
- Exchange
- CRBP Nasdaq
- NKTR Nasdaq
- Market Cap
- CRBP 96.5M
- NKTR 108.3M
- IPO Year
- CRBP N/A
- NKTR 1994
- Fundamental
- Price
- CRBP $8.22
- NKTR $24.25
- Analyst Decision
- CRBP Strong Buy
- NKTR Strong Buy
- Analyst Count
- CRBP 10
- NKTR 6
- Target Price
- CRBP $53.56
- NKTR $81.67
- AVG Volume (30 Days)
- CRBP 214.0K
- NKTR 4.8M
- Earning Date
- CRBP 08-05-2025
- NKTR 08-07-2025
- Dividend Yield
- CRBP N/A
- NKTR N/A
- EPS Growth
- CRBP N/A
- NKTR N/A
- EPS
- CRBP N/A
- NKTR N/A
- Revenue
- CRBP N/A
- NKTR $87,248,000.00
- Revenue This Year
- CRBP N/A
- NKTR N/A
- Revenue Next Year
- CRBP $150.03
- NKTR N/A
- P/E Ratio
- CRBP N/A
- NKTR N/A
- Revenue Growth
- CRBP N/A
- NKTR N/A
- 52 Week Low
- CRBP $4.64
- NKTR $6.48
- 52 Week High
- CRBP $61.90
- NKTR $37.38
- Technical
- Relative Strength Index (RSI)
- CRBP 54.23
- NKTR 63.40
- Support Level
- CRBP $7.26
- NKTR $21.87
- Resistance Level
- CRBP $7.90
- NKTR $26.59
- Average True Range (ATR)
- CRBP 0.53
- NKTR 4.14
- MACD
- CRBP -0.01
- NKTR 0.01
- Stochastic Oscillator
- CRBP 78.59
- NKTR 54.77
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.